Retrospective review of oral oncolytic agent use within a community hospital by Donadio, Alyssa et al.
Baptist Health South Florida
Scholarly Commons @ Baptist Health South Florida
All Publications
12-5-2018
Retrospective review of oral oncolytic agent use
within a community hospital
Alyssa Donadio
Baptist Hospital of Miami, AlyssaD@baptisthealth.net
Moe Shwin
Miami Cancer Institute, moes@baptisthealth.net
Maria Figueroa
Baptist Hospital of Miami, MariaF1@baptisthealth.net
Michelle Lamarque
Baptist Hospital of Miami, MichelleLam@baptisthealth.net
Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications
Part of the Chemical Actions and Uses Commons, Neoplasms Commons, and the Pharmacy
Administration, Policy and Regulation Commons
This Conference Poster -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been
accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more
information, please contact Carrief@baptisthealth.net.
Citation
Donadio, Alyssa; Shwin, Moe; Figueroa, Maria; and Lamarque, Michelle, "Retrospective review of oral oncolytic agent use within a
community hospital" (2018). All Publications. 3101.
https://scholarlycommons.baptisthealth.net/se-all-publications/3101
• Increasing availability of oral medications for the treatment 
of cancer offers many advantages.
• Delivery of these agents presents challenges including food 
and drug interactions, unique toxicities, education, and 
monitoring.
• At Baptist Hospital of Miami (BHM), parenteral 
chemotherapy administration occurs in the setting of strict 
prescribing standards, extensive verifications, and safe 
handling practices.
• The process of ordering, dispensing, and administration of 
oral chemotherapy agents has not been standardized 
throughout the institution.
• Quality and safety related to oral chemotherapy delivery has 
been recognized by organizations such as the American 
Society of Clinical Oncology (ASCO) as an important area of 
opportunity.
• Few studies currently exist to inform best practices, 
particularly among hospitalized patients.
To assess whether oral chemotherapeutic agents are being 
appropriately utilized in hospitalized patients and to determine 
potential areas for process improvement to ensure their safe 
and effective use.
• Single-center, IRB-exempt, retrospective chart review
• Inclusion criteria:
o Hospitalized adult patients > 18 years of age
o Order for an oral chemotherapy agent between May 1, 
2018 and June 30, 2018
• Exclusion criteria:
o Non-oncology indication for oral chemotherapy
• Primary outcome:
o Appropriateness of oral chemotherapy orders (defined 
as appropriate dose and treatment day, lack of major 
drug interactions or treatment-related toxicities) 
• Secondary outcomes:
o Total number of missed doses
o Time to oncology consultation
• Drug interactions were identified using the Lexicomp® Drug 
Interaction Tool
• Appropriate dose, treatment day, and treatment-related 
toxicities were evaluated based on available documentation 
in electronic medical record
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• This study demonstrated the need to standardize the process 
for oral chemotherapy ordering, dispensing, and 
administration at BHM.
• Most common reasons for inappropriate therapy included 
drug interactions, medication dose, and continuation of 
therapy despite treatment-related toxicities.
• Formulary agents and cases with oncology provider 
consultations were associated with increased likelihood of 
appropriate prescribing.
• Limitations:
o Information to assess outcomes was limited to 
documentation in electronic medical record
o Small sample size limited ability to assess most common 
agents
• Future directions/considerations based on study results:
o Pilot program for pharmacy-led inpatient oral 
chemotherapy monitoring service
o Request common non-formulary chemotherapy agents 
to be built into pharmacy system to allow clinical 
checking and hazardous drug alerts
o Provide education to pharmacists
o Recommend oncology consult in cases of potential 
medication related adverse events
Table 1. Patient Characteristics N=36
Demographics
Median age, years
Gender—female, n (%)
72 (range, 26-89)
24 (67%)
Median length of stay, days 6 (range, 1-104) 
Location: Oncology Unit, n (%) 12 (33)
Oncology Consult, n (%) 25 (69)
Oral Chemotherapy Indication, n (%)
Chronic Myeloid Leukemia (CML)
Acute Myeloid Leukemia (AML)
Breast Cancer
Lung Cancer
Acute Lymphoblastic Leukemia (ALL)
Multiple Myeloma
Myelodysplastic Syndrome (MDS)
Other
7 (19)
6 (17)
6 (17)
3 (8)
3 (8)
2 (6)
2 (6)
7 (19)
Table 2. Oral Chemotherapy Agents N=36
Formulary, n (%)
Imatinib
Hydroxyurea
Capecitabine
Temozolomide
9 (25)
5 (14)
2 (6)
1 (3)
1 (3)
Non-Formulary, n (%)
Midostaurin
Lenalidomide
Dasatinib
Palbociclib
Nilotinib
Ribociclib
Other
27 (75)
3 (8)
3 (8)
3 (8)
3 (8)
2 (6)
2 (6)
11 (31)
• 58% oral chemotherapy orders were appropriate
• Variety of opportunities for pharmacists to intervene, 
including:
o Optimizing administration with regard to food
o Identifying and managing major drug interactions
o Ensuring correct dose and day of treatment
o Recognizing significant treatment-related toxicities 
Table 3. Outcomes N=36
Primary Outcome, n (%)
Appropriate Therapy 21 (58)
Secondary Outcomes
Missed doses, total number
Median time to oncology consult, hrs
34
13 (range 0.5-23)
Suboptimal Therapy Categories, n (%)
Drug interactions (category D-X)
Inappropriate dose
Treatment-related toxicity
Wrong treatment day
Food interaction
8 (22)
5 (14)
5 (14)
1 (3)
16 (44)
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Table 4. Subgroup Analysis of Appropriate 
Therapy
Formulary Agent, n (%) 7/9 (78)
Non-Formulary Agent, n (%) 14/27 (52)
Oncology Consult, n (%) 18/25 (72)
No Oncology Consult, n (%) 3/11 (27)
